Promoted Content
Promoted Content

Find Gastroenterology Drugs in Phase II Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol

            Therapeutic Area: Gastroenterology Product Name: PPP-002

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tetra BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 21, 2020

            Details:

            Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apraglutide

            Therapeutic Area: Gastroenterology Product Name: FE203799

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Surveyor Capital

            Deal Size: $110.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 15, 2020

            Details:

            Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB004

            Therapeutic Area: Gastroenterology Product Name: GB004

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            Gossamer Bio will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which takes place from October 11th through 13th.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Blautia Hydrogenotrophica

            Therapeutic Area: Gastroenterology Product Name: Blautix

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            Details:

            The phase II trial showed that Blautix treatment resulted in: A statistically significant increase in overall response in pre-planned analysis of the combined IBS-C/D group compared to placebo; A positive, increase in overall response in both IBS-C and IBS-D cohorts.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lovastatin Lactone

            Therapeutic Area: Gastroenterology Product Name: SYN-010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 02, 2020

            Details:

            CSMC has decided discontinue the trial and will conduct a comprehensive review of the final data set, based on the review of the interim analysis. SYN-010 was well-tolerated but it is unlikely to meet its primary objective by the time enrollment is completed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sibofimloc

            Therapeutic Area: Gastroenterology Product Name: TAK-018

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            Sibofimloc was found to be well tolerated in healthy volunteers and in patients with Crohn’s disease in Phase 1 studies, which also generated first indications of target engagement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBT-401

            Therapeutic Area: Gastroenterology Product Name: BBT-401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            Company has confirmed both the safety and efficacy profiles of BBT-401 in active ulcerative colitis patients through the first cohort study of the Phase 2a trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine

            Therapeutic Area: Gastroenterology Product Name: ABX464

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRV-015

            Therapeutic Area: Gastroenterology Product Name: AMG 714

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            PRV-015 (anti-interleukin-15) is the first investigational product to show both a reduction in gluten-induced symptoms and in markers of intestinal inflammation in a placebo-controlled trial in celiac subjects .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMT-101

            Therapeutic Area: Gastroenterology Product Name: AMT-101

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            First patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severely active ulcerative colitis (UC).

            PharmaCompass